Featured Research

from universities, journals, and other organizations

In cancer, an embryonic gene-silencing mechanism gone awry

Date:
October 4, 2012
Source:
Ecole Polytechnique Fédérale de Lausanne
Summary:
Many types of cancer could originate from a mechanism that cells use to silence genes. This process, which is essential in embryonic development, might be accidentally reactivated in tumor cells, according to scientists.

There are some genes that are only activated in the very first days of an embryo's existence. Once they have accomplished their task, they are shut down forever, unlike most of our genes, which remain active throughout our lives. EPFL scientists have unveiled part of this strange mechanism. The same process, accidentally initiated later in life, could be responsible for many kinds of cancer. The discovery is described in a recent article in the journal Cell Reports.

The researchers identified a group of proteins that play a key role in this phenomenon. They bind to a DNA sequence near the gene, and substitute one DNA element for another, essentially "marking" the sequence. This phenomenon is known as "methylation." Once the marker is in place, the cellular machinery recognizes the sign and maintains the gene in a dormant state.

"It's an extremely elegant mechanism. The genes are needed right at the beginning of embryonic development, but rather than deactivate them every time a cell divides, the job is done in one fell swoop, once the genes are no longer required," explains EPFL professor Didier Trono, who co-authored the article. "This process is also involved in the control of viral sequences, which make up almost half of our genome, and must be inactivated very early in development."

This gene-silencing mechanism, which normally takes place in a several-day-old embryo, can also occur accidentally later in life. In many cancer cells, certain genes have been marked by methylation; they have been silenced. If, for example, the gene responsible for controlling cell division has been methylated, the consequences are all too easy to imagine. "The embryonic process, which is designed to silence certain genes, can be fortuitously reactivated, leading to the formation of tumor cells."

It is still not understood why the process stops after the first days of embryogenesis, even though many of the active proteins continue to be expressed in the cell, says Trono. "If we can figure out how this cellular clock works, then we would perhaps be able to understand how the mechanism is reactivated later, leading to the development of cancer."


Story Source:

The above story is based on materials provided by Ecole Polytechnique Fédérale de Lausanne. Note: Materials may be edited for content and length.


Journal Reference:

  1. Simon Quenneville, Priscilla Turelli, Karolina Bojkowska, Charlène Raclot, Sandra Offner, Adamandia Kapopoulou, Didier Trono. The KRAB-ZFP/KAP1 System Contributes to the Early Embryonic Establishment of Site-Specific DNA Methylation Patterns Maintained during Development. Cell Reports, 2012; DOI: 10.1016/j.celrep.2012.08.043

Cite This Page:

Ecole Polytechnique Fédérale de Lausanne. "In cancer, an embryonic gene-silencing mechanism gone awry." ScienceDaily. ScienceDaily, 4 October 2012. <www.sciencedaily.com/releases/2012/10/121004121548.htm>.
Ecole Polytechnique Fédérale de Lausanne. (2012, October 4). In cancer, an embryonic gene-silencing mechanism gone awry. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/10/121004121548.htm
Ecole Polytechnique Fédérale de Lausanne. "In cancer, an embryonic gene-silencing mechanism gone awry." ScienceDaily. www.sciencedaily.com/releases/2012/10/121004121548.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins